Friday, March 24, 2023 2:07:34 PM
Captain,
The options for the CAFC are either to affirm the District Court, or reverse the District Court and remand the case back to the District Court, where Hikma would be directed to file an Answer to Amarin's Complaint, and then the case would proceed to discovery, possible summary judgment, possible settlement talks, possible trial, all the stages of a normal case. Amarin does not have a cross-motion for summary judgment, so the CAFC will not make any reversal ruling other than remanding the case back to the District Court for the case to proceed as outlined above.
Amarin has couple of structural advantages in this Appeal that normal Appellants do not have, and these transcend the underlying merits:
1) The Magistrate Judge ruled in their favor, so instead of having just one lower court Opinion, we actually have a difference of opinion between two judges, giving Amarin the opportunity to parrot the Magistrate Judge and say that she got it right.
2) Motions to Dismiss without the benefit of discovery are generally disfavored and are usually not granted. To prevail, the Court has to conclude that that under no set of facts, does Amarin have a meritorious case against Hikma, and Hikma is entitled to prevail as a matter of law. That is essentially what Judge Andrews concluded.
But there are many cases where the Motion to Dismiss is denied, the parties conduct discovery, and then then case loses on summary judgment or at trial. Heck even in Judge Du's court, she did not grant summary judgment when she had the opportunity to do so. She ruled against Amarin after a full trial.
It is not a heavy bar for Amarin to meet in order for the CAFC to reverse and remand at this stage of the proceeding. Unless of course, Judges Dyk and Reyna preside for a third time, in which case, Rule 36 affirmance will inevitably be forthcoming within 24-48 hours after oral argument.
The options for the CAFC are either to affirm the District Court, or reverse the District Court and remand the case back to the District Court, where Hikma would be directed to file an Answer to Amarin's Complaint, and then the case would proceed to discovery, possible summary judgment, possible settlement talks, possible trial, all the stages of a normal case. Amarin does not have a cross-motion for summary judgment, so the CAFC will not make any reversal ruling other than remanding the case back to the District Court for the case to proceed as outlined above.
Amarin has couple of structural advantages in this Appeal that normal Appellants do not have, and these transcend the underlying merits:
1) The Magistrate Judge ruled in their favor, so instead of having just one lower court Opinion, we actually have a difference of opinion between two judges, giving Amarin the opportunity to parrot the Magistrate Judge and say that she got it right.
2) Motions to Dismiss without the benefit of discovery are generally disfavored and are usually not granted. To prevail, the Court has to conclude that that under no set of facts, does Amarin have a meritorious case against Hikma, and Hikma is entitled to prevail as a matter of law. That is essentially what Judge Andrews concluded.
But there are many cases where the Motion to Dismiss is denied, the parties conduct discovery, and then then case loses on summary judgment or at trial. Heck even in Judge Du's court, she did not grant summary judgment when she had the opportunity to do so. She ruled against Amarin after a full trial.
It is not a heavy bar for Amarin to meet in order for the CAFC to reverse and remand at this stage of the proceeding. Unless of course, Judges Dyk and Reyna preside for a third time, in which case, Rule 36 affirmance will inevitably be forthcoming within 24-48 hours after oral argument.
Recent AMRN News
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
